Why Attend?
The Fight Against Triple-Negative Breast Cancer
Breast cancer accounted for 28% of all new cancer cases and 14% of female cancer deaths in high-income countries in 2020. Triple-negative breast cancer (TNBC) is a subtype of breast cancer which occurs in 10-20% of newly diagnosed breast cancer cases but is disproportionately responsible for 30-40% of all breast cancer deaths. This is because the cells in TNBC don’t have receptors for estrogen or progesterone, nor do they make a lot of HER2 protein meaning they don’t respond to hormonal therapy or HER2 targeting therapies. The burden caused by this disease goes beyond its medical effects. TNBC and its treatments, both directly and indirectly, cause psychological distress, decline in the ability to function physically, body image issues, infertility, inability to work and, in turn, financial hardship.
Patient numbers of TNBC are expected to rise, with the Western world’s ageing population predicted to cause 10% more cases alone by 2040 with other factors such as obesity and inactivity expected to augment this further. The pressure this could put on unprepared, underfunded health systems could be catastrophic. Patients, clinicians and health infrastructures desperately need financial, strategic and legislative support from policymakers to save lives and lessen the societal impact. Europe’s Beating Cancer Plan and Screening Council Recommendations provide the basis for change towards better patient outcomes in Europe, the questions facing all stakeholders in the fight against TNBC are: Where is it best to target funding? How to prevent the root causes of the disease? What can be done to ensure patients are receiving the most effective care possible? And how can we improve access to innovative treatments?
This webinar hosted by the Financial Times, in partnership with MSD, will explore the medical, social and economic impact of TNBC, discuss the main challenges facing clinicians trying to save lives and identify what more is needed from policymakers in the fight against this disease.
Improving the care of women with triple-negative breast cancer
Premier Digital Events Supported by the World's Best Journalism
Using leading digital technology, we have now taken our content, global audience reach and engagement to a new level through a series of unmissable virtual events. Our compelling events are chaired by respected FT journalists, feature the most senior and thought-provoking decision-makers in business, finance and politics, all accessible from your office or home.
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice